Guidance for market authorization requirements for COVID-19 drugs: Rolling submissions and reviews (English, HTML)

View metadata and access the original English HTML file: Guidance for market authorization requirements for COVID-19 drugs: Rolling submissions and reviews.

Format

HTML

Access

file-only

Publisher-reported update

2022-07-28

Modified requirements for COVID-19 drugs allow for the filing of rolling submissions (section C.08.002(2.3) of Canada's Food and Drug Regulations). The ability to review data from early development while later-stage clinical trials are taking place helps to expedite the regulatory review process.

Access original file